SUPERNUS PHARMACEUTICALS, INC. Debt Conversion, Converted Instrument, Amount
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Debt Conversion, Converted Instrument, Amount of $26.02 million for the 9-month period ending 2015-09-30, per its 10-Q/A filed 2017-01-20.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2017-01-20
- SUPERNUS PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2015-09-30 was $963.00K, a 77.13% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2015-06-30 was $3.88M, a 1403.88% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2015-03-31 was $21.18M, a 103.26% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for the quarter ending 2014-12-31 was -$29.77M.
- SUPERNUS PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for fiscal 2014 was -$14.89M.
- SUPERNUS PHARMACEUTICALS, INC. debt conversion, converted instrument, amount for fiscal 2013 was -$42.42M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2015-09-30 | $963.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $4.84M derived: sum of 2 quarters · filed 2017-01-20 | $26.02M 10-Q/A · filed 2017-01-20 | -$3.75M derived: sum of 4 quarters · filed 2017-01-20 |
| 2015-06-30 | $3.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $25.06M 10-Q · filed 2015-08-07 | -$4.72M derived: sum of 3 quarters · filed 2015-08-07 | -$507.00K derived: sum of 4 quarters · filed 2017-01-20 |
| 2015-03-31 | $21.18M 10-Q · filed 2015-05-06 | -$8.60M derived: sum of 2 quarters · filed 2015-05-06 | -$4.39M derived: sum of 3 quarters · filed 2017-01-20 | -$4.13M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-12-31 | -$29.77M derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-03-12 | -$25.56M derived: sum of 2 quarters · filed 2017-01-20 | -$25.30M derived: sum of 3 quarters · filed 2017-01-20 | -$14.89M 10-K · filed 2015-03-12 |
| 2014-09-30 | $4.21M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | $4.47M derived: sum of 2 quarters · filed 2017-01-20 | $14.89M 10-Q/A · filed 2017-01-20 | |
| 2014-06-30 | $258.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $10.68M 10-Q · filed 2015-08-07 | ||
| 2014-03-31 | $10.42M 10-Q · filed 2015-05-06 | |||
| 2013-12-31 | -$42.42M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |